Cabernet Sauvig & Concord purple grape Juice: prom of non-amylo/Ho, Lap

该中心的总体目标是研究互补和替代 医学在阿尔茨海默病中的应用是鉴定葡萄源多酚在AD中的生物活性 预防和/或治疗Tg 2576小鼠阿尔茨海默病型Ap神经病理学模型， 认知能力下降本申请中提出的研究是基于我们的假设， 生物活性的葡萄衍生多酚可防止AD型认知障碍的发生和发展 通过抑制淀粉样前体蛋白产生A/7肽来抑制恶化。我们将测试这个 假设通过使用生物引导的分馏方法来产生多酚制剂， 赤霞珠和康科德紫葡萄汁的复杂度逐渐降低， 降低Tg 2576 AD小鼠模型中的活性。我们将继续探索ApMowering的功效 减轻Tg 2576中AD型认知恶化的发作和进展的多酚制剂 小鼠，并阐明其作用机制。 本申请中的拟议研究将补充本中心的其他研究项目 应用和阐明一般机制，葡萄衍生多酚可能会钝化年龄相关的 阿尔茨海默病，特别是在越来越多的受轻度认知障碍影响的人群中， AD的风险拟议研究的结果可能会导致选择性葡萄衍生的发展， 作为阿尔茨海默病临床试验先导化合物的多酚化合物

The overall objective of this Center of Excellence for Research on Complementary and Alternative Medicine in Alzheimer's disease application is to identify bioactive grape-derived polyhenols in AD prevention and/or therapy in the Tg2576 mouse model of Alzheimer's disease-type Ap neuropathology and cognitive deterioration. The proposed studies in this application are based on our hypothesize that selective bioactive grape-derived polyphenols protects against the onset and progression of AD-type cognitive deterioration by inhibiting the generation of A/7peptides from the amyloid precursor protein. We will test this hypothesis by using bio-guided fractionation methodologies to generate polyphenol preparations with progressively less complexity from Cabernet Sauvignon and from Concord purple grape juice that will exert A0- lowering activity in the Tg2576 AD mouse model. We will continue to explore the efficacy of ApMowering polyphenol preparations to attenuate the onset and progression of AD-type cognitive deterioration in Tg2576 mice and to clarify the mechanisms of action. The proposed studies in this application will complement the other Research Projects in this Center application and elucidate general mechanisms by which grape-derived polyphenolics may blunt age-related Alzheimer's disease, especially in a growing population affected by mild cognitive impairment that is at high risk for AD. Outcomes of the proposed studies will likely result in the development of selective grape-derived polyphenolic compounds as lead compounds for clinical testing in Alzheimer's disease